Kyung-Ah Kim is Executive Vice President and Leader of the Development Division at Samsung Bioepis. Kyung-Ah, a veteran scientist with more than 20 years of experience in biologic development, is responsible for overseeing all of Samsung Bioepis’ product development across various therapeutic areas. Prior to joining Samsung Bioepis, Kyung-Ah worked as Principal Scientist and later as Vice President at the Samsung Advanced Institute of Technology (SAIT), leading the Biotherapeutics Group and focusing on the development of antibody therapeutics targeting oncology. Before joining SAIT, she worked as a scientist / head of cell biology at multiple biopharmaceutical companies, leading various projects on the development of therapeutic agents, including genetic sequencing and profiling, development of drug screening assays, pre-clinical assessment, pharmacological assessment, and functional assessment of antibodies. Kyung-Ah holds a Ph.D. in neurotoxicology from Johns Hopkins University, where she established a signal transduction pathway, specifically in the learning impairment caused by genetic perturbation in lead poisoning.